Glycopyrronium (PT001) vs Oxitropium bromide (Ba253BINEB)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Glycopyrronium (PT001)

Developed by AstraZeneca

Phase 2/3 in Asthmasmall molecule
Partial signal

NCT03358147 · Phase 2/3 · completed

The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.

Next expected readout: May 2029 · NCT07525375 (registry estimate)

Reported efficacy

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)

Result source: NCT03358147

Oxitropium bromide (Ba253BINEB)

Developed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Weak signal

NCT02182661 · Phase 3 · completed

The study was an open-label, single-arm trial of 88 participants with no randomization or comparator group. Its primary outcomes were safety measures, but no results were posted, so there is no reported primary-endpoint comparison to assess.

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlycopyrronium (PT001)Oxitropium bromide (Ba253BINEB)
Severe exacerbations, annualised rate—Not reported—Not posted · NCT02182661
Trough FEV1, change0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
—Not posted · NCT02182661
ACQ-5, change-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
—Not posted · NCT02182661
OCS dose reduction—Not reported—Not posted · NCT02182661

Severe exacerbations, annualised rate

Glycopyrronium (PT001)
—Not reported
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661

Trough FEV1, change

Glycopyrronium (PT001)
0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661

ACQ-5, change

Glycopyrronium (PT001)
-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661

OCS dose reduction

Glycopyrronium (PT001)
—Not reported
Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Oxitropium bromide (Ba253BINEB): no structured comparison results are available for Asthma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Glycopyrronium (PT001): 4 of 4 rows · Oxitropium bromide (Ba253BINEB): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGlycopyrronium (PT001)
Dropout rate
14.5%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
16.3%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
14.2%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Discontinued due to AEs
1.3%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
3.8%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.9%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Serious AEs
3.8%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
2.9%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.5%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Most frequent reported AEs
28.8 μg
upper respiratory tract infection 6% (placebo 8%)
nasopharyngitis 4.7% (placebo 3.4%)
sinusitis 4.3% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
14.4 μg
nasopharyngitis 6.3% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 2.9% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
7.2 μg
nasopharyngitis 7.1% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 1.7% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Glycopyrronium (PT001)

FEV1 AUC0-4 0.294 vs 0.24 placebo L @ 24wk28.8 μg
absolute change · L
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.284 vs 0.24 placebo L @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.308 vs 0.24 placebo L @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
FEV1 Trough 0.142 vs 0.129 placebo L @ 24wk28.8 μg
absolute change · L
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.108 vs 0.129 placebo L @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.142 vs 0.129 placebo L @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Moderate to Severe Exacerbation Rate Annualized 0.43 vs 0.55 placebo per year @ 24wk28.8 μg
event rate · per year
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.44 vs 0.55 placebo per year @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.41 vs 0.55 placebo per year @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-7 -0.78 vs -0.8 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.73 vs -0.8 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-0.9 vs -0.8 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-5 -0.87 vs -0.93 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.8 vs -0.93 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-1.02 vs -0.93 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
AQLQ 0.89 vs 0.96 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.9 vs 0.96 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
1.02 vs 0.96 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Oxitropium bromide (Ba253BINEB)'s landscape